Video

CSCC: Escalating Therapy for High-risk Patients

Author(s):

Nikhil Kushalani, MD,Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute

Dr Vishal Patel shares a surgeon’s perspective on MDC, followed by a discussion on how intensifying treatment after surgery may improve outcomes for higher-risk patients with CSCC.

Related Videos
Alexander C. Van Akkooi, MD, PhD, FRACS
Related Content
The OncFive: OncLive's Top Oncology Articles for the Week of 1/19
January 25th 2025

The OncFive: Top Oncology Articles for the Week of 1/19

Yvonne Mowery, MD, PhD, physician scientist, associate professor, radiation oncology, University of Pittsburgh Medical Center Hillman Cancer Center
January 7th 2025

Pembrolizumab Plus Preoperative Radiotherapy and Surgery Improves DFS in Soft-Tissue Sarcoma: With Yvonne Mowery, MD, PhD

Pembrolizumab/Radiation/Surgery Improves DFS in Stage III Soft Tissue Sarcoma | Image Credit: © MdBabul - stock.adobe.com
January 18th 2025

Pembrolizumab/Radiation/Surgery Improves DFS in Stage III Soft Tissue Sarcoma

Onyee Chan, MD, hematologist/oncologist, Moffitt Cancer Center Magnolia Campus; Bradley D. Hunter, MD, medical director, Oncology, director, Immune Effector Cell Therapy, Intermountain Healthcare
December 24th 2024

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

Basal Cell Carcinoma | Maris– stock.adobe.com
January 8th 2025

Phase 3 Study of Ameluz-PDT in Superficial Basal Cell Carcinoma Reaches 1-Year Follow-Up to Support FDA sNDA Submission

This week’s top 5 includes a snapshot of FDA approvals from December, an exclusive roundup of critical NCCN guideline updates from 2024, and more.
January 4th 2025

The OncFive: Top Oncology Articles for the Week of 12/29